Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search

 

NZ dollar steady ahead of RBA speech, NZ rate decision

NZ dollar steady ahead of RBA speech, NZ rate decision

By Jenny Ruth

Sept. 24 (BusinessDesk) - The New Zealand dollar was little changed ahead of a key speech by the Reserve Bank of Australia's governor tonight and an official cash rate decision by the local central bank tomorrow.

The kiwi was trading at 62.96 US cents at 5:05pm in Wellington from 62.91 cents at 8:10am. The trade-weighted index was at 70.13 points from 70.08.

"It's been a quiet day, but it's also been one of subtle New Zealand dollar strength – overnight, it was one of, if not the best-performing OECD currency," says Peter Cavanaugh, the senior client advisor at Bancorp Treasury Services.

The level of short positions in the New Zealand dollar had reached record levels last week when the currency fell as low as 62.50 cents, its lowest level since September 2015.

Most of those positions are being unwound ahead of the end of the quarter later this month, so that strength should persist, Cavanaugh says.

"That pre-supposes there isn't another event offshore that prompts another burst of risk aversion," he says.

But it's all quiet on the US-China trade war front at the moment. Chinese negotiators left the US last week and high-level talks are expected to resume in early October.

German business confidence data and US consumer confidence numbers overnight mean "we might get a few speed-bumps" because these tend to be leading indicators of economic activity, Cavanaugh says.

Although US manufacturing data yesterday was mildly positive, counterpart data in Japan and Europe were weak, particularly in Germany where manufacturing contracted for a third consecutive month, boding ill for that country's GDP.

Germany's GDP contracted 0.1 percent in the June quarter and a second negative quarter would put that economy officially in recession.

RBA governor Philip Lowe is giving "An Economic Update" tonight and is expected to foreshadow a rate cut in early October.

The RBNZ is expected to hold its OCR steady tomorrow, although the market is pricing in a high probability of a rate cut in November.

The kiwi was trading at 92.88 Australian cents from 92.90, at 50.66 British pence from 50.60, at 57.29 euro cents from 57.24, at 67.75 yen from 67.61 and at 4.4786 Chinese yuan from 4.4772.

The two-year swap rate nudged up to a bid price of 0.9288 percent from 0.9234 yesterday while 10-year swaps rose to 1.2325 percent from 1.2275.

(BusinessDesk)

© Scoop Media

 
 
 
Business Headlines | Sci-Tech Headlines

 

Marine And Freshwater Reports: EDS Calls For Urgent Action On Marine Management

“There are some big issues to address. These include many marine species and habitats that are in serious trouble. Of the sample investigated, the report finds that 22% of marine mammals, 90% of seabirds and 80% of shorebirds are threatened with or actually at risk of extinction..." More>>

ALSO:

$7.5 Billion Surplus: Government Accounts "Show Strong Economy"

“The surplus and low levels of debt show the economy is in good shape. This allows the Government to spend more on infrastructure and make record investments in health and education,” Grant Robertson says. More>>

ALSO:

New OIO Application Trumps Judicial Review: OceanaGold Cleared To Buy Land For Waihi Tailings Expansion

In a surprise turnaround, the government has given OceanaGold a greenlight to buy land to expand its Waihi mine after the application was previously turned down by Land Information Minister Eugenie Sage. More>>

ALSO:

Christchurch Rebuild: Fletcher Sued For $7.5m Over Justice Precinct

Fletcher Building is being sued for $7.5 million by utilities contractor Electrix, one of the subcontractors on the Christchurch Justice and Emergency Services Precinct. More>>

Three New Drugs: PHARMAC Signs Bundle Deal For More Cancer Medicines

420 New Zealanders with lung cancer, breast cancer, multiple sclerosis and respiratory disease will benefit each year from a bundle deal PHARMAC has finalised with a medicine supplier. More>>

ALSO: